Kamat, A. M. et al. Bladder cancer. Lancet 388, 2796–2810 (2016).

Article  PubMed  Google Scholar 

Alfred Witjes, J. et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17–31 (2024).

Article  CAS  PubMed  Google Scholar 

Flaig, T. W. et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin. Cancer Res. 27, 2435–2441 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 67, 241–249 (2015).

Article  PubMed  Google Scholar 

Iyer, G. et al. Neoadjuvant gemcitabine–cisplatin plus radical cystectomy–pelvic lymph node dissection for muscle-invasive bladder cancer: a 12-year experience. Clin. Genitourin. Cancer 18, 387–394 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706–1714 (2019).

Article  CAS  PubMed  Google Scholar 

Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353–3360 (2018).

Article  CAS  PubMed  Google Scholar 

de Biasi, A. R., Villena-Vargas, J. & Adusumilli, P. S. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. 20, 5384–5391 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Rose, T. L. et al. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J. Clin. Oncol. 39, 3140–3148 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Funt, S. A. et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial. J. Clin. Oncol. 40, 1312–1322 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, T. et al. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. Cancer Immunol. Immunother. 67, 1079–1090 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye, D. et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Sci. 112, 305–313 (2021).

Article  CAS  PubMed  Google Scholar 

Robertson, A. G. et al. Comprehensive molecular characterization of muscle-Invasive bladder cancer. Cell 171, 540–556 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Plimack, E. R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959–967 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140–1153 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Adib, E. et al. CDKN2A alterations and response to immunotherapy in solid tumors. Clin. Cancer Res. 27, 4025–4035 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang, Q. et al. Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non-small cell lung cancer. Sci. Adv. 8, eabi9533 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu, Q. et al. Rheb1 protects against cisplatin-induced tubular cell death and acute kidney injury via maintaining mitochondrial homeostasis. Cell Death Dis. 11, 364 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teo, M. Y. et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 36, 1685–1694 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teo, M. Y. et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin. Cancer Res. 23, 3610–3618 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374–403 (2023).

Article  PubMed  Google Scholar 

Tian, B. et al. Curcumin inhibits urothelial tumor development by suppressing IGF2 and IGF2-mediated PI3K/AKT/mTOR signaling pathway. J. Drug Target. 25, 626–636 (2017).

Article  CAS  PubMed  Google Scholar 

Das, R. et al. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. Nat. Commun. 12, 4601 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Vitis, C. et al. ALDOC- and ENO2-driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis. J. Exp. Clin. Canc. Res. 42, 69 (2023).

Article  Google Scholar 

Januchowski, R. et al. Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed. Pharmacother. 68, 447–453 (2014).

Article  CAS  PubMed  Google Scholar 

Maddika, S. et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist. Updat. 10, 13–29 (2007).

Article  CAS  PubMed  Google Scholar 

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420–433 (2020).

Article  PubMed  Google Scholar 

Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, Z. et al. TTN/OBSCN ‘double‐hit’ predicts favourable prognosis, ‘immune‐hot’ subtype and potentially better immunotherapeutic efficacy in colorectal cancer. J. Cell. Mol. Med. 25, 3239–3251 (2021).

Article  CAS